ALS Limited delivered a strong result for FY26, with underlying net profit after tax from continuing operations reaching $381.2 million, representing growth of 25.8% against the prior corresponding period’s $303.0 million. The significant earnings expansion demonstrates improved operational performance across the business, with statutory net profit of $318.7 million also up 24.4% year on year. This profit growth occurred against a backdrop of revenue increases, with revenues from ordinary activities rising 10.7% to $3,320.1 million, signalling that ALS has not only expanded its top line but also improved operational leverage and cost management.
The earnings per share metrics reflect this profitability improvement, with basic underlying EPS from continuing operations climbing 21.2% to 75.7 cents and basic EPS increasing 19.9% to 63.3 cents. The divergence between underlying and statutory EPS of approximately 12 cents warrants investor attention, as it indicates the presence of non-continuing or non-recurring items. This gap suggests the core business performed even more robustly than the headline statutory figures suggest, with the difference attributable to discontinued operations or other adjustments outlined in the financial statements.
Shareholders will benefit from the improved profitability through enhanced dividend distributions. Total dividend per share for the year reached 42.5 cents, up 10.1% from the prior year, comprising a final dividend of 23.1 cents and an interim dividend of 19.4 cents. The final dividend carries a 30% franking level, with the Company noting that future dividends will be franked at the maximum level possible. The activation of the Dividend Reinvestment Plan at nil discount to the 5-day volume-weighted average price provides investors with the option to reinvest distributions without paying a premium, though the nil discount implies the market is pricing ALS fairly at present.
The balance sheet picture remains complicated by negative net tangible asset backing of 45 cents per security, though this represents a significant improvement from the prior year’s negative 157 cents. This swing of over 110 cents per share indicates substantial progress in working capital management or debt reduction, even if the Company’s tangible book value remains negative. This metric suggests investors are primarily valuing ALS on its earnings power and cash generation rather than accounting book value.
Investors should monitor the full financial statements for further detail on the composition of the non-continuing items, the trajectory of franking levels as the Company normalises post-recovery, and the capital management strategy going forward. This announcement has been flagged as price sensitive and material by the ASX.
View the full ASX announcement (PDF)
About ALS Limited (ASX: ALQ)
ALS Limited is a global leader in laboratory testing, inspection, certification, and verification services, operating from approximately 350 sites across 65 countries. The company operates two main divisions: Commodities, which provides assaying and metallurgical services for the mining sector, and Life Sciences, which offers analytical testing for environmental, food, pharmaceutical, and consumer products markets. Headquartered in Brisbane, Australia, ALS serves major clients across Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
